AssetMark Inc’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

AssetMark Inc’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-345	Closed	-$27.3K	–	3627
2026 Q1	$27.3K	Buy	345 +20	+6%	+$1.62K	﹤0.01%	1950
2025 Q4	$26.7K	Hold	325	–	–	﹤0.01%	1912
2025 Q3	$22.7K	Hold	325	–	–	﹤0.01%	1877
2025 Q2	$20.8K	Hold	325	–	–	﹤0.01%	1795
2025 Q1	$20.6K	Hold	325	–	–	﹤0.01%	1700
2024 Q4	$21.6K	Hold	325	–	–	﹤0.01%	1634
2024 Q3	$22.7K	Hold	325	–	–	﹤0.01%	1473
2024 Q2	$21.1K	Buy	+325	New	+$20.6K	﹤0.01%	1382
2016 Q3	–	Sell	-30	Closed	-$1K	–	1264
2016 Q2	$1K	Sell	30 -22	-42%	-$863	﹤0.01%	1135
2016 Q1	$2K	Hold	52	–	–	﹤0.01%	1073
2015 Q4	$3K	Buy	+52	New	+$2.57K	﹤0.01%	1048

Other funds holding PBE

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return

PIM

Penobscot Investment Management Boston, Massachusetts $1.46B AUM 32.32% 1-Year Est. Return

MWM

Massachusetts Wealth Management North Andover, Massachusetts $262M AUM 48.07% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

AssetMark Inc's PBE Position: Q2 2026 in Review

AssetMark Inc sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2026, closing a stake of 345 shares — an estimated $27.3K sold.

AssetMark Inc first reported a position in PBE in Q4 2015 and held it in 11 quarters. The position peaked at $27.3K in Q1 2026. 34 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

AssetMark Inc reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2026 after selling out during the quarter.
AssetMark Inc sold 345 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $27.3K.
AssetMark Inc first reported a position in Invesco Biotechnology & Genome ETF in Q4 2015 and held it in 11 quarters.
AssetMark Inc's Invesco Biotechnology & Genome ETF position peaked at $27.3K in Q1 2026.
34 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.